Application 018703

Type
NDA
Sponsor
GLAXO GRP LTD

Application Products#

Product, Drug, Ingredient table
ProductDrugIngredientFormStrengthReference drugReference standard
001ZANTAC 150RANITIDINE HYDROCHLORIDETABLET;ORALEQ 150MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**YesNo
002ZANTAC 300RANITIDINE HYDROCHLORIDETABLET;ORALEQ 300MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**YesNo

NDC Listings For This Application#

NDC, Name, Nonproprietary name table
NDCNameNonproprietary nameLabelerMarketing categoryStatus
0173-0393ZANTACranitidine hydrochlorideGlaxoSmithKline LLCNDACurrent

Documents#

Document, Submission type, Date table
DocumentSubmission typeDate
1033SUPPL2009-11-12
11286SUPPL2009-10-06
11285SUPPL2009-03-27
15101SUPPL2009-02-19
1032SUPPL2006-07-21
15100SUPPL2005-05-02
11284SUPPL2005-05-02
15099SUPPL2004-07-01
20150SUPPL2003-04-30
1031SUPPL2002-01-07